

Resource Summary Report

Generated by [NIF](#) on Sep 4, 2026

PLK1 (208G4) Rabbit mAb

RRID:AB_2167409

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4513, RRID:AB_2167409

Antibody Information

URL: http://antibodyregistry.org/AB_2167409

Proper Citation: Cell Signaling Technology Cat# 4513, RRID:AB_2167409

Target Antigen: PLK1

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P. Consolidation on 11/2018: AB_10693801, AB_10828721, AB_2167409.

Antibody Name: PLK1 (208G4) Rabbit mAb

Description: This monoclonal targets PLK1

Target Organism: rat, human

Clone ID: Clone 208G4

Antibody ID: AB_2167409

Vendor: Cell Signaling Technology

Catalog Number: 4513

Record Creation Time: 20231110T044343+0000

Record Last Update: 20260831T203630+0000

Ratings and Alerts

No rating or validation information has been found for PLK1 (208G4) Rabbit mAb.

No alerts have been found for PLK1 (208G4) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 29 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Nguyen TT, et al. (2026) NN-01-195, a Novel Conjugate of HSP90 and AURKA Inhibitors, Effectively Targets Solid Tumors. *Molecular cancer therapeutics*, 25(8), 1231.

Korns J, et al. (2026) Targeting PLK1 Reduces MMP10 to Enhance Radiosensitivity in HPV- Head and Neck Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(2), 405.

Yamanaka S, et al. (2026) An interactome-based framework for DDB1- and CUL4-associated factor prioritization in targeted protein degradation. *Molecular cell*, 86(7), 1397.

Neill NJ, et al. (2025) Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer. *Cancer discovery*, 15(11), 2326.

Williams I, et al. (2025) MYC and HSF1 Cooperate to Drive Sensitivity to Polo-like Kinase 1 Inhibitor Volasertib in High-grade Serous Ovarian Cancer. *Cancer research communications*, 5(2), 253.

Sahasrabuddhe AA, et al. (2025) The FBXO45-GEF-H1 Axis Controls Germinal Center Formation and B-cell Lymphomagenesis. *Cancer discovery*, 15(4), 838.

Zhao B, et al. (2025) PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma. *Cell reports*, 44(4), 115541.

Kang X, et al. (2025) Extrachromosomal DNA replication and maintenance couple with DNA damage pathway in tumors. *Cell*, 188(13), 3405.

Haight JA, et al. (2024) Auranofin and reactive oxygen species inhibit protein synthesis and regulate the level of the PLK1 protein in Ewing sarcoma cells. *bioRxiv : the preprint server for biology*.

Pan Q, et al. (2024) Mapping functional elements of the DNA damage response through base editor screens. *Cell reports*, 43(12), 115047.

Wang Z, et al. (2024) Molecular subtypes of neuroendocrine carcinomas: A cross-tissue classification framework based on five transcriptional regulators. *Cancer cell*, 42(6), 1106.

Haight JA, et al. (2024) Auranofin and reactive oxygen species inhibit protein synthesis and regulate the level of the PLK1 protein in Ewing sarcoma cells. *Frontiers in oncology*, 14, 1394653.

Chen M, et al. (2024) Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling. *Cell reports. Medicine*, 5(7), 101645.

He Y, et al. (2024) Targeting ATAD3A Phosphorylation Mediated by TBK1 Ameliorates Senescence-Associated Pathologies. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e2404109.

Lin XT, et al. (2023) Elevated FBXW10 drives hepatocellular carcinoma tumorigenesis via AR-VRK2 phosphorylation-dependent GAPDH ubiquitination in male transgenic mice. *Cell reports*, 42(7), 112812.

Patterson JC, et al. (2023) Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling. *Cancer research*, 83(2), 219.

Tammaccaro SL, et al. (2023) TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC. *Pharmaceuticals* (Basel, Switzerland), 16(4).

Wang R, et al. (2023) Kinome-wide CRISPR-Cas9 knockout screens revealed PLK1 as a therapeutic target for osteosarcoma. *Cell death discovery*, 9(1), 231.

Chang SC, et al. (2022) Targeted degradation of PCNA outperforms stoichiometric inhibition to result in programmed cell death. *Cell chemical biology*, 29(11), 1601.

Metselaar DS, et al. (2022) AURKA and PLK1 inhibition selectively and synergistically block cell cycle progression in diffuse midline glioma. *iScience*, 25(6), 104398.